Liver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.
Primary care professionals can “substantially expand” HCV treatment in the community, according to new research.
A new report highlights key missing elements needed to achieve complete elimination of hepatitis C virus.
A sustained response to direct-acting antivirals lowers the risk of hepatocellular carcinoma, a new study finds.
Sofosbuvir-based therapy successfully treats HCV patients with decompensated liver disease, according to a new study.
New research finds direct-acting antivirals can be given safely to those on liver transplant waitlist.
Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
A shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.
New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.